AstraZeneca received approval from the FDA for Seroquel for the maintenance treatment of patients with bipolar I disorder, as adjunct therapy to lithium or divalproex. Seroquel is approved by the FDA for the treatment of schizophrenia, and both depressive episodes in bipolar disorder and acute manic episodes associated with bipolar I disorder.     The FDA approval was based on two multicenter, randomized, double-blind, placebo-controlled trials that evaluated Seroquel when used as an adjunct...